PLUS THERAPEUTICS, INC. — Director's Dealing 2016

Jun 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTORI THERAPEUTICS, INC. (CYTX)
CIK: 0001095981
Period of Report: 2016-06-15

Reporting Person: KESTEN STEVEN (Exec VP and Chief MO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-15	Common Stock	X	200	—	Acquired	3481	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-15	Subscription Rights (Right to Buy)	$2.55	X	200	Disposed	2016-06-10	See Footnote (200)	Direct
2016-06-15	Warrants (Right to Buy)	$3.06	X	100	Acquired	2018-12-14	Common Stock (100)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	400	Indirect

Footnotes

F1: Shares held directly by Steven Kesten and Barbara Mary Kesten, trustees of The Kesten Living Trust Dated January 31, 2002, a trust for the benefit of the Reporting Person and the Reporting Person's spouse, for which the Reporting Person and the Reporting Person's spouse serve as trustees.

F2: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company) to all holders of the Company's common stock. The subscription rights entitled each recipient thereof to purchase units ("Units"). Each Unit consists of one share of the Company's common stock and 0.5 of a warrant, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $2.55.

F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $3.06 from the date of issuance through December 14, 2018.